Vascular Endothelial Growth Factor 1 as a Predictor for Adverse Cardiovascular Events in Patients with Arterial Hypertension III Stage. The Results of One-Year Follow-up. Part II

A.Ye. Berezin, O.A. Lisovaya


The aim of the study was to investigate the predictive value of serial measurements of circulating vascular endothelial growth factor 1 (VEGF) level in stage III hypertensive patients.
Materials and Methods. One hundred and two patients with mild to moderate arterial hypertension III stage within 3 weeks after ische-mic stroke were included into the study. Follow-up was 12 months with a 3 month intervals. The circulating VEGF-1 level was assessed at baseline and after six months. Clinical interviews were conducted every 3 months for 1 year after receiving blood samples. As a clinical point we determined follow cardiovascular outcomes: recurrent stroke or transient ischemic attack, ischemic heart disease, sudden death, diabetes mellitus, cardiovascular events, including chronic heart failure, and the need for hospitalization for these reasons.
Results. The analysis of obtained outcomes have shown that increased VEGF-1 concentration within six months after ischemic stroke has been positively associated with incidence of cardiovascular events, when compared with individuals without increased circulating levels of VEGF-1. Adjusted odds ratio for the occurrence of cumulative cardiovascular events in stage III hypertension patients with VEGF-1 at baseline more 403.57 pg/ml, when compared with lower concentrations of it was 4.11 (95% CI = 2.66–7.28; P = 0.001), and an increased sixth month circulating VEGF-1 over 450.15 pg/ml, when compared with lower concentrations of it was associated with adjusted odds ratio 5.46 (95% CI = 3.12–7.90; P = 0.001).
Conclusion. Circulating vascular endothelial growth factor 1 level is an independent predictor of one-year cumulative cardiovascular events in patients with stage III hypertension after cerebral ischemic stroke.


vascular endothelial growth factor 1; ischemic stroke; arterial hypertension; serial measurements; clinical outcomes; predicted value


Березин A.E., Лисовая O.A. Васкулярный эндотелиальный фактор роста 1 как предиктор неблагоприятных кардиоваскулярных событий у пациентов с гипертонической болезнью III стадии. Результаты одногодичного наблюдения. Часть I // Международный неврологический журнал. — 2014. — № 1(63). — 61-67.

Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., Marsh E.E. III. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment // Stroke. — 1993. — 24. — 35-41.

American College of Cardiology Foundation/American Heart Association Task Force; American Stroke Association; American Association of Neuroscience Nurses; American Association of Neurological Surgeons; American College of Radiology; American Society of Neuroradiology; Congress of Neurological Surgeons; Society of Atherosclerosis Imaging and Prevention; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of NeuroInterventional Surgery; Society for Vascular Medicine; Society for Vascular Surgery; American Academy of Neurology; Society of Cardiovascular Computed Tomography. Brott T.G., Halperin J.L., Abbara S., Bacharach J.M., Barr J.D., Bush R.L., Cates C.U., Creager M.A., Fowler S.B., Friday G., Hertzberg V.S., McIff E.B., Moore W.S., Panagos P.D., Riles T.S., Rosenwasser R.H., Taylor A.J., 2011. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary // J. Neurointerv. — Surg. — 2011. — 3(2). — 100-130.

Collin C., Wade D.T., Davies S., Horne V. The Barthel ADL Index: a reliability study // Int. Disabil. Stud. — 1988. — 10. — 61-63.

Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G., Schneider D., Diez-Tejedor E., Trouillas P., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) // Lancet. — 1998. — 352. — 1245-1251.

Hayashi T., Abe K., Itoyama Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia // J. Cereb. Blood Flow Metab. — 1998. — 18(8). — 887-895.

Hermann D.M., Zechariah A. Implications of vascular endothelial growth factor for postischemic neurovascular remodeling // J. Cereb. Blood Flow Metab. — 2009. — 29. — 1620-1643.

Lo E.H. A new penumbra: transitioning from injury into repair after stroke // Nat. Med. — 2008. — 14. — 497-500.

Luo Y., Wang Z., Li J., Xu Y. Serum CRP concentrations and severity of ischemic stroke subtypes // Can. J. Neurol. Sci. — 2012. — 39(1). — 69-73.

Luque A., Carpizo D.R., Iruela-Arispe M.L. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165 // J. Biol. Chem. — 2003. — 278. — 23656-23665.

Lyden P.D., Lu M., Levine S., Brott T.G., Broderick J. A modified National Institutes of Health stroke scale for use in stroke clinical trials. Preliminary reliability and validity // Stroke. — 2001. — 32. — 1310-1317.

Merrill M.J., Oldfield E.H. A reassessment of vascular endothelial growth factor in central nervous system pathology // J. Neurosurg. — 2005. — 103(5). — 853-868.

Orecchia A., Lacal P.M., Schietroma C. et al. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin // J. Cell. Sci. — 2003. — 116. — 3479-3489.

Sacks D.B., Arnold M., Bakris G.L., Bruns D.E., Horvath A.R., Kirkman M.S, Lernmark A., Metzger B.E., Nathan D.M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus // Clin. Chem. — 2011. — 57(6). — 1-47.

Sun Y., Jin K., Xie L., Childs J., Mao X.O., Logvinova A., Greenberg D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia // J. Clin. Invest. — 2003. — 111. — 1843-1851.

Testa U., Pannitteri G., Condorelli G.L. Vascular endothelial growth factors in cardiovascular medicine // J. Cardiovasc. Med. — 2008. — 9. — 1190-1221.

Williams S.V., Fihn S.D., Gibbons R.J. American College of Cardiology; American Heart Association; American College of Physicians-American Society of Internal Medicine. Guidelines for the management of patients with chronic stable angina: diagnosis and risk stratification // Ann. Intern. Med. — 2001. — 135(7). — 530-547.

Zhao H., Bao X.J., Wang R.Z., Li G.L., Gao J., Ma S.H., Wei J.J., Feng M., Zhao Y.J., Ma W.B., Yang Y., Li Y.N., Kong Y.G. Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats // Hum. Gene Ther. — 2011. — 22. — 207-215.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта